Alphatec (ATEC) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 07, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ATEC	'
Entity Registrant Name	'Alphatec Holdings, Inc.	'
Entity Central Index Key	'0001350653	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	97,561,668

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$18,654	$22,241
Accounts receivable, net	41,738	41,012
Inventories, net	43,139	49,855
Prepaid expenses and other current assets	6,069	5,953
Deferred income tax assets	2,874	2,991
Total current assets	112,474	122,052
Property and equipment, net	29,515	30,403
Goodwill	181,390	180,838
Intangibles, net	40,744	46,856
Other assets	2,012	1,978
Total assets	366,135	382,127
Current liabilities:	'	'
Accounts payable	14,171	15,237
Accrued expenses	35,952	38,490
Deferred revenue	1,264	1,361
Current portion of long-term debt	4,984	1,700
Total current liabilities	56,371	56,788
Long-term debt, less current portion	43,784	39,967
Other long-term liabilities	11,130	13,485
Deferred income tax liabilities	2,277	2,468
Redeemable preferred stock, $0.0001 par value; 20,000 authorized at September 30, 2013 and December 31, 2012; 3,319 shares issued and outstanding at both September 30, 2013 and December 31, 2012	23,603	23,603
Stockholders' equity:	'	'
Common stock, $0.0001 par value; 200,000 authorized at September 30, 2013 and December 31, 2012; 97,453 and 96,703 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	10	10
Treasury stock, 19 shares	-97	-97
Additional paid-in capital	402,250	399,246
Accumulated other comprehensive (loss) income	2,082	112
Accumulated deficit	-175,275	-153,455
Total stockholders' equity	228,970	245,816
Total liabilities and stockholders' equity	$366,135	$382,127

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Redeemable preferred stock, par value	$0.00	$0.00
Redeemable preferred stock, shares authorized	20,000,000	20,000,000
Redeemable preferred stock, shares issued	3,319,000	3,319,000
Redeemable preferred stock, shares outstanding	3,319,000	3,319,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	97,453,000	96,703,000
Common stock, shares outstanding	97,453,000	96,703,000
Treasury stock, shares	19,000	19,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenues	$50,196	$46,839	$151,659	$143,535
Cost of revenues	25,532	16,844	61,303	50,773
Amortization of acquired intangible assets	432	362	1,289	1,114
Gross profit	24,232	29,633	89,067	91,648
Operating expenses:	'	'	'	'
Research and development	3,028	3,216	10,376	11,003
Sales and marketing	18,149	17,778	55,804	55,843
General and administrative	11,443	9,758	34,018	28,714
Amortization of acquired intangible assets	741	491	2,255	1,574
Transaction related expenses	0	364	0	364
Restructuring Charges	4,045	0	4,045	0
Total operating expenses	37,406	31,607	106,498	97,498
Operating loss	-13,174	-1,974	-17,431	-5,850
Other income (expense):	'	'	'	'
Interest income	2	33	4	108
Interest expense	-1,048	-774	-2,670	-5,060
Other income (expense), net	210	208	-840	-61
Total other income (expense)	-836	-533	-3,506	-5,013
Loss from continuing operations before taxes	-14,010	-2,507	-20,937	-10,863
Income tax provision (benefit)	500	-38	883	-759
Net loss	($14,510)	($2,469)	($21,820)	($10,104)
Net loss per common share:	'	'	'	'
Basic and diluted net loss per share, in dollars per share	($0.15)	($0.03)	($0.23)	($0.11)
Weighted-average shares used in computing net loss per share:	'	'	'	'
Basic and diluted, in shares	96,381	89,503	96,046	89,222

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($14,510)	($2,469)	($21,820)	($10,104)
Foreign currency translation adjustments	4,737	4,825	1,970	505
Comprehensive loss	($9,773)	$2,356	($19,850)	($9,599)

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities:	'	'
Net loss	($21,820)	($10,104)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization	19,964	17,423
Stock-based compensation	2,832	2,210
Interest expense related to amortization of debt discount and debt issuance costs	285	849
Provision for doubtful accounts	225	858
Provision for excess and obsolete inventory	10,842	3,980
Deferred income tax benefit	-269	-1,507
Other noncash items	1,252	1,890
Changes in operating assets and liabilities:	'	'
Accounts receivable	-1,704	3,368
Inventories	-4,720	-5,675
Prepaid expenses and other current assets	1,627	1,194
Other assets	57	714
Accounts payable	-1,921	162
Accrued expenses and other	172	-3,660
Deferred revenues	-153	189
Net cash provided by operating activities	6,669	11,891
Investing activities:	'	'
Purchases of property and equipment	-10,975	-12,010
Purchase of intangible assets	-750	0
Cash paid for acquisitions	-4,000	-825
Net cash used in investing activities	-15,725	-12,835
Financing activities:	'	'
Exercise of stock options	0	16
Borrowings under lines of credit	109,283	82,881
Repayments under lines of credit	-130,017	-65,225
Principal payments on notes payable and capital lease obligations	-1,705	-12,180
Proceeds from notes payable	28,000	0
Net cash provided by financing activities	5,561	5,492
Effect of exchange rate changes on cash and cash equivalents	-92	727
Net increase (decrease) in cash and cash equivalents	-3,587	5,275
Cash and cash equivalents at beginning of period	22,241	20,666
Cash and cash equivalents at end of period	18,654	25,941
Supplemental cash flow information:	'	'
Cash paid for interest	2,759	1,799
Cash paid for income taxes	804	633
Purchases of property and equipment in accounts payable	2,087	3,199
Property and equipment purchased under capital lease	$0	$1,650

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
The Company and Basis of Presentation	'
	The Company and Basis of Presentation
	The Company
	Alphatec Holdings, Inc. (“Alphatec”, “Alphatec Holdings” or the “Company”), through its wholly owned subsidiary, Alphatec Spine, Inc. and its subsidiaries (“Alphatec Spine”), designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its affiliate, Scient’x S.A.S. and its subsidiaries (“Scient’x”), via a direct sales force in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In South America and Latin America, the Company conducts its operations through its Brazilian subsidiary, Cibramed Productos Medicos. In Asia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. and its subsidiaries (“Alphatec Pacific”), via a direct sales force and independent distributors, and through distributors in other parts of Asia and Australia.
	Basis of Presentation
	The accompanying condensed consolidated balance sheet as of December 31, 2012, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual audited financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made in this quarterly report on Form 10-Q are adequate to make the information not misleading. The interim unaudited condensed consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the financial position and results of operations for the periods presented. All such adjustments are of a normal and recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2012, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 that was filed with the SEC on March 4, 2013.
	Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013, or any other future periods.
	The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. A going concern basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. Based on the Company’s annual operating plan, management believes that its existing cash and cash equivalents of $18.7 million combined with anticipated cash flow from operations in 2013 and other working capital of $37.4 million at September 30, 2013 will be sufficient to fund its cash requirements through at least September 30, 2014. The Company’s amended credit facility (the “Amended Credit Facility”) with MidCap Financial, LLC (“MidCap”) contains financial covenants consisting of a monthly fixed charge coverage ratio and a senior leverage ratio (see Note 6).
	Based on the Company’s current operating plan, the Company believes that it will be in compliance with the financial covenants of the Amended Credit Facility at least through September 30, 2014. However, there is no assurance that the Company will be able to do so. If the Company is not able to achieve its planned revenue or incurs costs in excess of its forecasts, it may be required to substantially reduce discretionary spending and it could be in default of the Amended Credit Facility, which would require a waiver from MidCap. There can be no assurance that such a waiver could be obtained, that the Amended Credit Facility could be successfully renegotiated or that the Company could modify its operations to maintain liquidity. If the Company is unable to obtain any required waivers or amendments, MidCap would have the right to exercise remedies specified in the Amended Credit Facility, including accelerating the repayment of debt obligations. The Company may be forced to seek additional financing, such as additional debt and/or equity financing or funding through other third party agreements. There can be no assurances that additional financing would be available on acceptable terms or available at all. Furthermore, any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	The Company’s significant accounting policies are described in Note 2 to its audited consolidated financial statements for the year ended December 31, 2012, which are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 4, 2013. Except as discussed below, these accounting policies have not significantly changed during the nine months ended September 30, 2013.
	Impairment Analysis of Goodwill
	The Company performs its test for goodwill impairment annually during the fourth quarter and in interim periods if certain events occur indicating that the carrying value of goodwill may be impaired. During the quarter ended September 30, 2013, the Company concluded that the announcement of the Scient’x restructuring plan (Note 12) was an indicator of a potential impairment in goodwill. As a result, the Company performed an interim impairment test on its single operating unit.
	The goodwill impairment test is a two-step process. The first step compares the Company’s fair value to its net book value. If the fair value is less than the net book value, the second step of the test compares the implied fair value of the Company’s goodwill to its carrying amount. If the carrying amount of goodwill exceeds its implied fair value, the Company would recognize an impairment loss equal to that excess amount.
	The Company estimated the fair value in step one based on the income approach which included discounted cash flows as well as a market approach that utilized the Company’s earnings and revenue multiples and recent sales transactions. The Company’s discounted cash flows required management judgment with respect to forecasted sales, launch of new products, gross margin, selling, general and administrative expenses, capital expenditures and the selection and use of an appropriate discount rate. The Company utilized its weighted average cost of capital as the discount rate for the projected future cash flows and its median revenue and earnings multiples under the market approach. The Company’s assessment resulted in a fair value that was greater than the Company’s carrying value at September 30, 2013. In accordance with the authoritative literature, the second step of the impairment test was not required to be performed and no impairment of goodwill was recorded as of September 30, 2013.
	Significant management judgment is required in the forecast of future operating results that are used in the Company’s impairment analysis. The estimates the Company used are consistent with the plans and estimates that it uses to manage its business going forward. Significant assumptions utilized in the Company’s income approach model included the revenue growth rate for existing products, the introduction of newly launched and anticipated products, the projected regional mix of higher margin U.S. based revenues and lower margin non-U.S. based revenues, and the projected improvement in its gross margin based on product, channel and  regional mix combined with long-term manufacturing efficiency gains. The estimated fair value of the Company as calculated in the third quarter interim test could be materially affected, both negatively and positively, with significant changes to the discount rate and other key forward looking  assumptions. The Company will re-assess goodwill impairment when it performs its annual test for impairment in December 31, 2013.
	Impairment of Long-Lived Assets
	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived assets is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results. During the quarter ended September 30, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name, Puregen. The company also decided that it would no longer actively market one of its minimally invasive surgery products. The Company expensed $1.1 million as impairment charges in cost of goods sold in the three and nine months ended September 30, 2013 for the write-off of intangible assets related to these products.
	Due to the Scient'x restructuring plan, the Company assessed potential impairment on certain intangible assets related to the Scient'x acquisition. Based on this assessment the projected undiscounted cash flows exceeded the carrying amount of the intangible assets and no impairment loss was recognized in the three and nine months ended September 30, 2013.
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments will be effective for the Company beginning January 1, 2014. We do not anticipate any impact on our financial statements upon adoption.
	In February 2013, the FASB issued guidance that requires a company to disaggregate the total change of each component of other comprehensive income either on the face of the income statement or as a separate disclosure in the notes thereto. The new guidance became effective for the Company’s interim period ended March 31, 2013. The Company adopted this guidance and the adoption did not have any impact on its financial position, results of operations or cash flows.
	In July 2013, the FASB issued guidance that requires an unrecognized tax benefit, or a portion of an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless an exception applies. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2013. The Company will reflect the impact of these amendments beginning with the Company's Quarterly Report on Form 10-Q for the period ending March 31, 2014. The Company does not anticipate a material impact to the Company's financial position, results of operations or cash flows as a result of this change.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	Acquisition of Phygen, LLC
	On November 6, 2012, the Company closed the transactions contemplated by the Asset Purchase Agreement (the “Asset Purchase Agreement”) with Phygen, LLC (“Phygen”), pursuant to which the Company agreed to purchase Phygen’s right, title and interest in and certain assets used by Phygen in connection with the design, development, marketing and distribution of certain of Phygen’s spinal implant products, together with the intellectual property rights, contractual rights, inventories and certain liabilities related thereto. At the closing of the transaction the Company issued to Phygen 4,069,087 unregistered shares of the Company’s common stock and paid to Phygen $2 million in cash. The Company placed 1,170,960 unregistered shares of the common stock into an escrow account, which will serve as security against any potential indemnification obligations of Phygen under the Asset Purchase Agreement for a period of 12 months following the closing. In addition, pursuant to the Asset Purchase Agreement, the Company paid to Phygen $4 million in cash in April 2013.
	Based on the closing price of Alphatec’s common stock of $1.69 per share on November 6, 2012, cash consideration and contingent liabilities, the total purchase price for Phygen was as follows (in thousands):
	Fair value of Alphatec common stock issued upon closing	$	8,856
	Cash consideration paid and payable	5,900
	Contingent consideration	3,724
	Total purchase price	$	18,480
	Under the acquisition method of accounting, the total purchase price allocated to Phygen’s net tangible and intangible assets was based on their estimated fair values on the closing date of the acquisition.
	The following table summarizes the allocation of the purchase price of Phygen and the estimated useful lives for the acquired intangible assets (in thousands):
		Useful lives		Estimated
		(in years)		Fair Value
	Net tangible assets assumed			$	1,086
	Acquired intangibles:
	Developed technology	3		176
	Trademarks	3		59
	Covenant not-to-compete	3		389
	Customer-related intangibles	12		5,843
	Distribution network	12		2,413
	Goodwill			8,514
	Total purchase price allocation			$	18,480
	The Company allocated $1.1 million to Phygen’s net tangible assets assumed, $8.9 million to identifiable intangible assets acquired and $3.7 million to contingent consideration. A value of $8.5 million, representing the difference between the total purchase price and the aggregate fair values assigned to the net tangible and intangible assets acquired, less liabilities and contingent consideration assumed, was assigned to goodwill. The Company acquired Phygen to expand its product offerings to Phygen’s existing surgeon base. This and other factors contributed to a purchase price for Phygen that resulted in the recognition of goodwill. The amount recorded as acquired intangibles and goodwill is expected to be deductible for tax purposes.
	The Company increased the value of inventory it acquired from Phygen to its estimated fair value (“inventory step-up”), which represented an amount equivalent to estimated selling prices for the inventory less distribution related costs and a normative selling profit. Consistent with stock rotation, the inventory step-up was amortized to cost of revenue ratably over six months and is included in the Company’s post-combination financial statements.
	For the technology-related assets, the Company determined the values for each of these categories by estimating the present values of the net cash flows expected to be generated by each category of technology.
	The Company calculated the value of the trademark by estimating the present value of future royalty costs that would be avoided by a market participant due to ownership of the trademarks acquired.
	The Company calculated the value of the covenant not-to-compete by estimating the difference between the present value of future cash flows with and without the covenant not-to-compete in place.
	The customer-related intangibles include hospitals and distributors that take title to Phygen’s products. The Company determined the value of such customer-related intangibles by estimating the present value of expected future net cash flows derived from such customers.
	The distribution network includes U.S.-based distributors that provide Phygen’s products to customers on a consignment basis. The Company determined the value of the intangibles related to the distribution network by estimating the difference between the present values of expected future net cash flows generated with and without the distribution network in place.
	The Company calculated the value of the contingent consideration by estimating the present value of future minimum royalty payments due under licensing agreements entered into in connection with the Phygen acquisition. The Company will revalue the contingent consideration each reporting period with an offset to any increase or decrease in the statement of operations. This is a Level 3 measurement as significant assumptions used in the measurement include estimates of the royalty payments due.
	Pro forma supplemental financial information is not provided as the impact of the Phygen acquisition was not material to operating results in the three and nine months ended September 30, 2012.

Select_Balance_Sheet_Details

Select Balance Sheet Details	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Select Balance Sheet Details	'
	Select Balance Sheet Details
	Accounts Receivable, net
	Accounts receivable, net consist of the following (in thousands):
		September 30, 2013				December 31, 2012
	Accounts receivable	$	42,717			$	42,086
	Allowance for doubtful accounts	(979		)		(1,074		)
	Accounts receivables, net	$	41,738			$	41,012
	Inventories, net
	Inventories, net consist of the following (in thousands):
		September 30, 2013										December 31, 2012
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	5,291			$	—			$	5,291	$	5,863	$	—		$	5,863
	Work-in-process	519				—				519		1,350		—			1,350
	Finished goods	61,439				(24,110		)		37,329		59,864		(17,222		)	42,642
	Inventories	$	67,249			$	(24,110	)		$	43,139	$	67,077	$	(17,222	)	$	49,855
	Property and Equipment, net
	Property and equipment, net consist of the following (in thousands except as indicated):
		Useful lives		September 30,				December 31,
		(in years)		2013				2012
	Surgical instruments	4		$	63,119			$	56,712
	Machinery and equipment	7		14,630				13,996
	Computer equipment	3		3,352				3,269
	Office furniture and equipment	5		3,714				3,528
	Leasehold improvements	various		4,177				4,092
	Building	39		56				64
	Land	n/a		11				13
	Construction in progress	n/a		336				1,045
				89,395				82,719
	Less accumulated depreciation and amortization			(59,880		)		(52,316		)
	Property and equipment, net			$	29,515			$	30,403
	Total depreciation expense was $3.7 million and $3.5 million for the three months ended September 30, 2013 and 2012, respectively. Total depreciation expense was $10.9 million and $10.5 million for the nine months ended September 30, 2013 and 2012, respectively.
	Intangible Assets, net
	Intangible assets, net consist of the following (in thousands except as indicated):
		Useful lives		September 30,				December 31,
		(in years)		2013				2012
	Developed product technology	8-Mar		$	23,475			$	23,253
	Distribution rights	3		2,480				4,281
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		17,186				17,423
	Core technology	10		5,053				4,940
	Trademarks and trade names	9-Mar		3,868				3,796
	Customer-related	15-Dec		21,923				19,221
	Distribution network	12-Oct		4,027				3,906
	Physician education programs	10		3,109				3,039
	Supply agreement	10		225				225
				82,350				81,088
	Less accumulated amortization			(41,606		)		(34,232		)
	Intangible assets, net			$	40,744			$	46,856
	Total amortization expense was $3.7 million and $2.3 million for the three months ended September 30, 2013 and 2012, respectively. Total amortization expense was $9.1 million and $6.9 million for the nine months ended September 30, 2013 and 2012, respectively.
	Future amortization expense related to intangible assets subject to amortization are as follows (in thousands):
	Year Ending December 31,
	Remainder of 2013	$	3,266
	2014	6,121
	2015	5,638
	2016	5,320
	2017	4,945
	Thereafter	15,454
		$	40,744
	Goodwill
	The changes in the carrying amount of goodwill from December 31, 2012 through September 30, 2013 are as follows (in thousands):
	Balance at December 31, 2012	$	180,838
Change in Phygen goodwill	(1,610		)
Effect of foreign exchange rate on goodwill	2,162
Balance at September 30, 2013	$	181,390

License_and_Supply_Agreements

License and Supply Agreements	9 Months Ended
	Sep. 30, 2013
Contractors [Abstract]	'
License and Supply Agreements	'
	License and Supply Agreements
	The Company’s license and developmental consulting agreements are described in Note 5 to its audited consolidated financial statements for the year ended December 31, 2012, which are included in its Annual Report on Form 10-K which was filed with the SEC on March 4, 2013.
	Distribution Agreement with Parcell Spine, LLC
	In January 2010, the Company entered into an exclusive distribution agreement (the “Parcell Agreement”) with Parcell Spine, LLC (“Parcell Spine”), which provided the Company with the exclusive right to distribute Parcell Spine’s proprietary adult stem cells for the treatment of spinal disorders under either Parcell’s trademarks or Alphatec Spine’s trademarks. The financial terms of the Parcell Agreement included: (i) a cash payment of $0.5 million payable following the execution of the Parcell Agreement; (ii) a milestone payment consisting of $1.0 million in cash and the issuance of $1.0 million of shares of the Company’s common stock following the successful completion of a pre-clinical study; and (iii) sales milestone payments in cash and the Company’s common stock. During the third quarter of 2010, the Company recorded an intangible asset of $1.5 million for a milestone payment required upon market launch when the product became commercially ready for sale which consisted of a cash payment of $0.5 million and the issuance of 476,190 shares of the Company’s common stock.
	During the quarter ended September 30, 2013, the Company decided that it would not continue to sell its Puregen product, which is currently the only product commercialized by the Company under the Parcell Agreement. In the three and nine months ended September 30, 2013, the Company expensed $0.9 million as impairment charges in cost of goods for the write-off of intangible assets related to the Parcell Agreement and expensed $2.6 million related to the write-off of inventory and certain prepaid assets in cost of goods sold.

Debt

Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	Loan and Security Agreement
	On August 30, 2013, the Company entered into an Amended and Restated Credit, Security and Guaranty Agreement (the "Amended Credit Facilty") with MidCap. The Amended Credit Facility amended and restated the prior credit facility that the Company had MidCap (the "Credit Facility").
	Pursuant to the Amended Credit Facility, the Company increased the borrowing limit from $50 million to $73 million. The Company also extended the maturity to August 2016. The Amended Credit Facility consists of a $28 million term loan drawn at closing with a $5 million delayed draw within 12 months, for a total term loan maximum borrowing of $33 million and a revolving line of credit with a maximum borrowing base of $40 million. The Company used the term loan proceeds of $28 million to repay a portion of the outstanding balance on the prior revolving line of credit.
	The term loan interest rate is priced at the London Interbank Offered Rate ( "LIBOR") plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate remains priced at LIBOR plus 6.0%, reset monthly. At September 30, 2013, the revolving line of credit carried an interest rate of 6.2% and the term loan carries an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries.
	In addition to monthly payments of interest, monthly repayments of $0.3 million of the principal for the term loan are due beginning in October 2013 through maturity, with the remaining principal due upon maturity.
	In connection with the execution of the Amended Credit Facility, the Company incurred approximately $0.4 million in costs that are capitalized as debt issuance costs within the unaudited consolidated balance sheets as of September 30, 2013. Approximately $0.4 million of the net remaining unamortized debt issuance costs related to the prior Credit Facility remain within the unaudited consolidated balance sheets, which will be amortized over the term of the Amended Credit Facility.
	On June 7, 2012, the Company entered into the Credit Facility with MidCap, which permitted the Company to borrow up to $40 million under a revolving line of credit and included an option to increase the borrowing base to $50 million with the prior consent of MidCap. As collateral for the Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries.
	Upon execution of the Credit Facility, the Company drew $34.3 million on the Credit Facility to pay off its existing term loan with Silicon Valley Bank (“SVB”) totaling $8.1 million and its existing line of credit with SVB totaling $17.6 million (collectively the “SVB Credit Facility”). The Company paid early termination and other fees to SVB associated with the SVB Credit Facility of $2.3 million and wrote-off $0.6 million of unamortized debt issuance and debt discount costs related to the SVB Credit Facility. The total loss on extinguishment of debt costs of $2.9 million is included in interest expense in the nine months ended September 30, 2012. The Company paid an up-front commitment fee to MidCap of $0.2 million and debt issuance costs of $0.2 million, which were capitalized as deferred debt issuance costs.
	The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio and a senior leverage ratio to be maintained by the Company. The Amended Credit Facility also includes several potential events of default, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable. In January 2013, the Company entered into a limited waiver and limited consent agreement with MidCap (the “Waiver”). Under the Waiver, MidCap gave the Company its consent to waive certain provisions of the Credit Facility in connection with the acquisition of Phygen and related to the maintenance of cash balances in the U.S. In February 2013, the Company and MidCap entered into a first amendment to the Credit Facility (the First Amendment”). The First Amendment allowed the Company to exclude payments related to the Phygen acquisition and the settlement agreement with Cross Medical Products, LLC (“Cross”) from calculation of the fixed charge coverage ratio and the senior leverage ratio. In conjunction with the First Amendment, the Company paid MidCap a fee of $0.1 million. In July 2013, the Company entered into a second limited waiver and limited consent agreement with MidCap (the “Second Waiver”). Under the Second Waiver, MidCap gave the Company its consent to waive certain provisions of the Credit Facility related to the maintenance of cash balances in the U.S. for past periods through September 30, 2013. The Company was in compliance with all of the covenants of the Amended Credit Facility as of September 30, 2013.
	Principal payments on debt are as follows as of September 30, 2013 (in thousands):
	Year Ending December 31,
	Remainder of 2013	$	1,340
	2014	3,964
	2015	3,000
	2016	39,026
	2017	—
	Thereafter	—
	Total	47,330
	Add: capital lease principal payments	1,438
	Total	48,768
	Less: current portion of long-term debt	(4,984		)
	Long-term debt, net of current portion	$	43,784

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	The Company leases certain equipment under capital leases which expire on various dates through June 2017. The leases bear interest at rates ranging from 6.6% to 9.6%, are generally due in monthly principal and interest installments and are collateralized by the related equipment. The Company also leases its buildings and certain equipment and vehicles under operating leases which expire on various dates through February 2018. Future minimum annual lease payments under such leases are as follows (in thousands):
	Year Ending December 31,	Operating		Capital
	Remainder of 2013	$	1,014	$	132
	2014	3,431		527
	2015	2,768		466
	2016	1,369		423
	2017	216		82
	Thereafter	15		—
		$	8,813	1,630
	Less: amount representing interest			(192		)
	Present value of minimum lease payments			1,438
	Current portion of capital leases			(430		)
	Capital leases, less current portion			$	1,008
	Rent expense under operating leases for the three months ended September 30, 2013 and 2012 was $0.9 million and $0.9 million, respectively. Rent expense under operating leases for the nine months ended September 30, 2013 and 2012 was $2.9 million and $2.8 million, respectively.
	Litigation
	In 1998, Eurosurgical, a French company in the business of sales and marketing of spinal implants, entered into a distribution agreement for the United States, Mexico, Canada, India and Australia with Orthotec, LLC, a California company (“Orthotec”). In 2004, Orthotec sued Eurosurgical in connection with a contractual dispute and a final $9 million judgment was entered against Eurosurgical by a California court in 2006. In 2007, following a default judgment, a federal court in California declared Eurosurgical liable to Orthotec for $30 million in connection with an intellectual property dispute. In 2006, Eurosurgical’s European assets were ultimately acquired by Surgiview, SAS, or Surgiview, in a sale agreement, or the Partial Sale Agreement, approved by a French court. After this sale, Surgiview became a subsidiary of Scient’x in 2006. Orthotec attempted to recover on Eurosurgical’s obligations by filing a motion in a California court to add Surgiview to the judgment against Eurosurgical on theories including successor liability and fraudulent conveyance. In February 2007, the California court denied Orthotec’s motion, indicating that Orthotec had not carried its burdens of proof. Orthotec chose to not proceed with a further hearing in September 2007.
	In June 2004, HealthpointCapital (Luxembourg) I S.à.r.l. acquired a minority (33.1 percent) interest in Scient’x. In July 2005, Scient’x acquired an approximately 73 percent interest in Surgiview. At that time, HealthpointCapital Partners, L.P. (through a Luxembourg subsidiary) held a minority interest in Scient’x, which in turn held an interest in Surgiview, but HealthpointCapital Partners II, L.P. had no ownership interest in Scient’x or Surgiview. On November 21, 2007, more than a year after the Partial Sale Agreement was executed, HealthpointCapital Partners II, L.P. acquired majority ownership of Scient’x. In May 2008, after the acquisition of Scient’x by HealthpointCapital in 2007, Orthotec sued Scient’x, Surgiview, HealthpointCapital LLC and certain former directors of Scient’x (who also serve on the Company’s board) in a new action in California state court in which it sought (in addition to damages related to other causes of action and punitive damages related thereto) to have the defendants bear responsibility for the $39 million in judgments that had been assessed against Eurosurgical, which, together with interest is now greater than $55 million. In April 2009, the California court dismissed this matter on jurisdictional grounds, and Orthotec appealed the ruling. In December 2010, the California Court of Appeal issued a decision that affirmed in part and reversed in part the trial court’s decision dismissing the entire California action based on lack of personal jurisdiction. The Court of Appeal affirmed the trial court’s ruling that Orthotec failed to establish personal jurisdiction over all parties except Surgiview, finding that the trial court could exercise jurisdiction over that entity. In January 2012, Orthotec amended its complaint and added the Company as a defendant to the California matter asserting claims against the Company based on its 2010 acquisition of Scient’x. Alphatec filed a motion for summary judgment in November 2012. This motion was denied in March 2013. The case was scheduled for trial in September 2013; however, such trial has been rescheduled to January 2, 2014.
	In addition, also in May 2008, a similar action was filed in New York against HealthpointCapital, HealthpointCapital LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., Scient’x and two former directors of Scient’x (who also serve on the Company’s board), in which Orthotec sought, in addition to damages related to other causes of action and punitive damages related thereto, to have the defendant’s bear responsibility for the $39 million in judgments that had been assessed against Eurosurgical, which, together with interest is now greater than $55 million. In July 2009, Orthotec voluntarily dismissed Scient’x from the action. In November 2009, the court dismissed Orthotec’s claims based on collateral estoppel, and Orthotec appealed this ruling. In March 2011, the state appeals court reversed the lower court’s decision to dismiss Orthotec’s claims. The New York matter then proceeded with discovery, and the defendants filed a motion for summary judgment in December 2012. The motion for summary judgment was granted in part and denied in part. A notice of appeal has been filed with respect to the portion of the motion for summary judgment that was denied and a motion has been filed to stay this matter pending the resolution of such appeal. This motion has not been decided. Additionally, the defendants filed a motion to dismiss one of the plaintiff’s claims based upon Orthotec’s spoliation of evidence, which motion was denied. That denial was appealed, however the appeal was denied. Since March 2010, the Company has been paying legal costs that have been incurred with the New York matter in connection with the obligation to indemnify the two former directors of Scient'x.
	While the Company intends to vigorously defend against these actions, and believes that the plaintiff’s allegations are without merit, the outcome of the litigations cannot be predicted at this time and any outcome in favor of Orthotec, regardless of who the defendant is, could have a significant adverse effect on the Company’s financial condition and results of operations.
	On August 25, 2010, an alleged shareholder of the Company’s filed a derivative lawsuit in the Superior Court of California, San Diego County, purporting to assert claims on behalf of the Company against all of its directors and certain of its officers and HealthpointCapital. Following the filing of this complaint, similar complaints were filed in the same court and in the U.S. District Court for the Southern District of California against the same defendants containing similar allegations. The complaint filed in federal court was dismissed by the plaintiff without prejudice in July 2011. The plaintiff amended its complaint and re-filed it in April 2012. This amended complaint was dismissed with prejudice in March 2013. In April 2013 the plaintiff filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit. The state court complaints have been consolidated into a single action. The Company has been named as a nominal defendant in the consolidated action. Each complaint alleges that the Company’s directors and certain of its officers breached their fiduciary duties to the Company related to the Scient’x transaction, and by making allegedly false statements that led to unjust enrichment of HealthpointCapital and certain of the Company’s directors. The complaints seek unspecified monetary damages and an order directing the Company to adopt certain measures purportedly designed to improve its corporate governance and internal procedures. The Company believes the claims are without merit and intends to vigorously defend itself against these complaints; however no assurances can be given as to the timing or outcome of this lawsuit.
	At September 30, 2013, the probable outcome of any of the aforementioned litigation matters cannot be determined nor can the Company estimate a range of potential loss. Accordingly, in accordance with the authoritative guidance on the evaluation of contingencies, the Company has not recorded an accrual related to these litigation matters. The Company is and may become involved in various other legal proceedings arising from its business activities. While management does not believe the ultimate disposition of these matters will have a material adverse impact on the Company’s consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of these proceedings, an unfavorable resolution could materially affect the Company’s future consolidated results of operations, cash flows or financial position in a particular period.
	Royalties
	The Company has entered into various intellectual property agreements requiring the payment of royalties based on the sale of products that utilize such intellectual property. These royalties primarily relate to products sold by Alphatec Spine and are calculated either as a percentage of net sales or in one instance on a per-unit sold basis. Royalties are included on the accompanying condensed consolidated statement of operations as a component of cost of revenues.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013				2012			2013			2012
	Numerator:
	Net loss	$	(14,510	)		$	(2,469	)	$	(21,820	)	$	(10,104	)
	Denominator:
	Weighted average common shares outstanding	97,318				90,216			96,940			89,812
	Weighted average unvested common shares subject to repurchase	(937		)		(713		)	(894		)	(590		)
	Weighted average common shares outstanding—basic	96,381				89,503			96,046			89,222
	Effect of dilutive securities:
	Options, warrants and restricted share awards	—				—			—			—
	Weighted average common shares outstanding—diluted	96,381				89,503			96,046			89,222
	Net loss per common share:
	Basic and diluted net loss per share	$	(0.15	)		$	(0.03	)	$	(0.23	)	$	(0.11	)
	The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Options to purchase common stock	2,383			4,754			4,355		4,773
	Unvested restricted share awards	937			713			894		590
	Total	3,320			5,467			5,249		5,363

Equity_Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Equity Transactions	'
	Equity Transactions
	Media Advertising Agreement
	In May 2013, the Company entered into an additional consulting agreement with a third-party entity for marketing and advertising services. In connection with this agreement the Company paid the consultant total cash consideration of $0.2 million and issued 225,000 restricted shares of the Company’s common stock.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	To calculate its interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. In addition, the effect of changes in enacted tax laws or rates or tax status is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the tax environment changes.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company’s unrecognized tax benefits increased $0.7 million during the nine months ended September 30, 2013. The increase in unrecognized tax benefits during the nine months ended September 30, 2013 was primarily related to an increase related to federal and state research credits and uncertain tax positions within the Company’s foreign subsidiaries. The unrecognized tax benefits at September 30, 2013 were $6.6 million. With the facts and circumstances currently available to the Company, it is reasonably possible that the amount that could reverse over the next 12 months is insignificant. Utilization of the French net operating loss carryforwards may become subject to limitation due to the restructuring. These limitations may limit the amount of the net operating loss carryforwards that can be utilized to offset future taxable income
	The income tax provision consists primarily of income tax provisions related to state income taxes, the tax effect of changes in deferred tax liabilities associated with tax deductible goodwill and operations in other foreign jurisdictions where the Company operates.
	The Company is undergoing an exam of the 2011 tax year by the IRS. The Company is not currently under examination by foreign or state and local tax authorities.

Segment_and_Geographical_Infor

Segment and Geographical Information	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment and Geographical Information	'
	Segment and Geographical Information
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and one reportable business segment.
	During the three and nine months ended September 30, 2013 and 2012, the Company operated in two geographic regions, the U.S. and International, which consists of locations outside of the U.S. In the International geographic region, sales in Japan for the three and nine months ended September 30, 2013 totaled $7.3 million and $20.8 million, respectively, which in each case represented greater than 10 percent of the Company’s consolidated revenues for their respective periods. For the three and nine months ended September 30, 2012, sales in Japan totaled $7.5 million and $21.0 million, respectively, which in each case represented greater than 10 percent of the Company’s consolidated revenues for their respective periods.
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	United States	$	33,696	$	30,980	$	99,249	$	96,430
	International	16,500		15,859		52,410		47,105
	Total consolidated revenues	$	50,196	$	46,839	$	151,659	$	143,535
	Total assets by region were as follows (in thousands):
		September 30,		December 31,
		2013		2012
	United States	$	195,708	$	213,912
	International	170,427		168,215
	Total consolidated assets	$	366,135	$	382,127

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	Restructuring
	On September 16, 2013, the Company announced that Scient'x has begun a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. The restructuring includes an expected reduction in Scient'x's workforce and closing of the manufacturing facilities in France. The Company estimates that it will record total costs, including employee severance, social plan benefits and related taxes, facility closing costs, manufacturing transfer costs, and contract termination costs of approximately $11 million associated with this restructuring. In accordance with ASC Topic 420, Accounting for Costs Associated with Exit or Disposal Activities and ASC Topic 712, Non retirement Postemployment Benefits, the Company has recorded a restructuring charge accrual in accrued expenses of $4.0 million within the consolidated balance sheets as of September 30, 2013 and restructuring expenses within the consolidated statements of operations for the three and nine months ending September 30, 2013. The Company estimates that it will record facility closing and contract termination costs of up to approximately $11 million. The Company expects to complete all the activities associated with the restructuring activities by the end of the second quarter of 2014, a substantial portion of which will be paid by then.
	In connection with the restructuring plan, the Company modified its estimate of inventory and instrument net book value at its Scient'x entities based on revised global demand. The Company recorded an additional inventory reserve of $4.5 million in the three and nine months ended September 30, 2013 included in cost of goods sold within the consolidated statements of operations.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	For the nine months ended September 30, 2013, the Company incurred expenses of $0.1 million and had a liability of $0.1 million payable to HealthpointCapital, LLC for travel and administrative expenses.
	The Company has entered into indemnification agreements with certain of its directors which are named defendants in the New York Orthotec matter (See Note 7 – Commitments and Contingencies – Litigation). The indemnification agreements require the Company to indemnify these individuals to the fullest extent permitted by applicable law and to advance expenses incurred by them in connection with any proceeding against them with respect to which they may be entitled to indemnification by the Company. For the nine months ended September 30, 2013 and 2012, the Company incurred legal expenses of approximately $1.3 million and $1.9 million, respectively, in connection with the Company’s indemnification obligations to two former directors of Scient'x in the New York Orthotec matter.

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Event	'
	Subsequent Event
	On October 22, 2013, the Company entered into a three-year collaboration agreement with a third party to provide consultation services to assist the Company in the development of it's products and it's products in development. Under the terms of the collaboration agreement, the Company will gain exclusive rights to the use of all intellectual property developed by the collaborators. The Company will make three annual payments to the collaborator as sole consideration for services provided, totaling an aggregate of up to $8 million, paid in common stock of Alphatec Holdings at a per share price of $1.95, which was equal to the average NASDAQ closing price of the common stock on the five days leading up to and including the date of signing the collaboration agreement. The actual number of shares issued each year will be determined by the fair market value of the services provided over the prior 12 months.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Impairment Analysis of Goodwill	'
	Impairment Analysis of Goodwill
	The Company performs its test for goodwill impairment annually during the fourth quarter and in interim periods if certain events occur indicating that the carrying value of goodwill may be impaired. During the quarter ended September 30, 2013, the Company concluded that the announcement of the Scient’x restructuring plan (Note 12) was an indicator of a potential impairment in goodwill. As a result, the Company performed an interim impairment test on its single operating unit.
	The goodwill impairment test is a two-step process. The first step compares the Company’s fair value to its net book value. If the fair value is less than the net book value, the second step of the test compares the implied fair value of the Company’s goodwill to its carrying amount. If the carrying amount of goodwill exceeds its implied fair value, the Company would recognize an impairment loss equal to that excess amount.
	The Company estimated the fair value in step one based on the income approach which included discounted cash flows as well as a market approach that utilized the Company’s earnings and revenue multiples and recent sales transactions. The Company’s discounted cash flows required management judgment with respect to forecasted sales, launch of new products, gross margin, selling, general and administrative expenses, capital expenditures and the selection and use of an appropriate discount rate. The Company utilized its weighted average cost of capital as the discount rate for the projected future cash flows and its median revenue and earnings multiples under the market approach. The Company’s assessment resulted in a fair value that was greater than the Company’s carrying value at September 30, 2013. In accordance with the authoritative literature, the second step of the impairment test was not required to be performed and no impairment of goodwill was recorded as of September 30, 2013.
	Significant management judgment is required in the forecast of future operating results that are used in the Company’s impairment analysis. The estimates the Company used are consistent with the plans and estimates that it uses to manage its business going forward. Significant assumptions utilized in the Company’s income approach model included the revenue growth rate for existing products, the introduction of newly launched and anticipated products, the projected regional mix of higher margin U.S. based revenues and lower margin non-U.S. based revenues, and the projected improvement in its gross margin based on product, channel and  regional mix combined with long-term manufacturing efficiency gains. The estimated fair value of the Company as calculated in the third quarter interim test could be materially affected, both negatively and positively, with significant changes to the discount rate and other key forward looking  assumptions. The Company will re-assess goodwill impairment when it performs its annual test for impairment in December 31, 2013.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived assets is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results. During the quarter ended September 30, 2013, the Company decided that it would not continue to market an adult stem cell product sold under the Company's private label name, Puregen. The company also decided that it would no longer actively market one of its minimally invasive surgery products. The Company expensed $1.1 million as impairment charges in cost of goods sold in the three and nine months ended September 30, 2013 for the write-off of intangible assets related to these products.
	Due to the Scient'x restructuring plan, the Company assessed potential impairment on certain intangible assets related to the Scient'x acquisition. Based on this assessment the projected undiscounted cash flows exceeded the carrying amount of the intangible assets and no impairment loss was recognized in the three and nine months ended September 30, 2013.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments will be effective for the Company beginning January 1, 2014. We do not anticipate any impact on our financial statements upon adoption.
	In February 2013, the FASB issued guidance that requires a company to disaggregate the total change of each component of other comprehensive income either on the face of the income statement or as a separate disclosure in the notes thereto. The new guidance became effective for the Company’s interim period ended March 31, 2013. The Company adopted this guidance and the adoption did not have any impact on its financial position, results of operations or cash flows.

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Purchase Price Consideration Based on Common Stock and Cash Consideration	'
	Based on the closing price of Alphatec’s common stock of $1.69 per share on November 6, 2012, cash consideration and contingent liabilities, the total purchase price for Phygen was as follows (in thousands):
	Fair value of Alphatec common stock issued upon closing	$	8,856
	Cash consideration paid and payable	5,900
	Contingent consideration	3,724
	Total purchase price	$	18,480
Allocation of Purchase Price and Estimated Useful Life of Assets Acquired	'
	The following table summarizes the allocation of the purchase price of Phygen and the estimated useful lives for the acquired intangible assets (in thousands):
		Useful lives		Estimated
		(in years)		Fair Value
	Net tangible assets assumed			$	1,086
	Acquired intangibles:
	Developed technology	3		176
	Trademarks	3		59
	Covenant not-to-compete	3		389
	Customer-related intangibles	12		5,843
	Distribution network	12		2,413
	Goodwill			8,514
	Total purchase price allocation			$	18,480

Select_Balance_Sheet_Details_T

Select Balance Sheet Details (Tables)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Accounts Receivable, Net	'
	Accounts receivable, net consist of the following (in thousands):
		September 30, 2013				December 31, 2012
	Accounts receivable	$	42,717			$	42,086
	Allowance for doubtful accounts	(979		)		(1,074		)
	Accounts receivables, net	$	41,738			$	41,012
Inventories, Net	'
	nventories, net
	Inventories, net consist of the following (in thousands):
		September 30, 2013										December 31, 2012
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	5,291			$	—			$	5,291	$	5,863	$	—		$	5,863
	Work-in-process	519				—				519		1,350		—			1,350
	Finished goods	61,439				(24,110		)		37,329		59,864		(17,222		)	42,642
	Inventories	$	67,249			$	(24,110	)		$	43,139	$	67,077	$	(17,222	)	$	49,855
Property and Equipment, Net	'
	Property and Equipment, net
	Property and equipment, net consist of the following (in thousands except as indicated):
		Useful lives		September 30,				December 31,
		(in years)		2013				2012
	Surgical instruments	4		$	63,119			$	56,712
	Machinery and equipment	7		14,630				13,996
	Computer equipment	3		3,352				3,269
	Office furniture and equipment	5		3,714				3,528
	Leasehold improvements	various		4,177				4,092
	Building	39		56				64
	Land	n/a		11				13
	Construction in progress	n/a		336				1,045
				89,395				82,719
	Less accumulated depreciation and amortization			(59,880		)		(52,316		)
	Property and equipment, net			$	29,515			$	30,403
Intangible Assets, Net	'
	Intangible assets, net consist of the following (in thousands except as indicated):
		Useful lives		September 30,				December 31,
		(in years)		2013				2012
	Developed product technology	8-Mar		$	23,475			$	23,253
	Distribution rights	3		2,480				4,281
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		17,186				17,423
	Core technology	10		5,053				4,940
	Trademarks and trade names	9-Mar		3,868				3,796
	Customer-related	15-Dec		21,923				19,221
	Distribution network	12-Oct		4,027				3,906
	Physician education programs	10		3,109				3,039
	Supply agreement	10		225				225
				82,350				81,088
	Less accumulated amortization			(41,606		)		(34,232		)
	Intangible assets, net			$	40,744			$	46,856
Schedule of Intangible assets, future amortization expense	'
	Future amortization expense related to intangible assets subject to amortization are as follows (in thousands):
	Year Ending December 31,
	Remainder of 2013	$	3,266
	2014	6,121
	2015	5,638
	2016	5,320
	2017	4,945
	Thereafter	15,454
		$	40,744
Schedule of Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill from December 31, 2012 through September 30, 2013 are as follows (in thousands):
	Balance at December 31, 2012	$	180,838
	Change in Phygen goodwill	(1,610		)
	Effect of foreign exchange rate on goodwill	2,162
	Balance at September 30, 2013	$	181,390

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Principal Payments on Debt	'
	Principal payments on debt are as follows as of September 30, 2013 (in thousands):
	Year Ending December 31,
	Remainder of 2013	$	1,340
	2014	3,964
	2015	3,000
	2016	39,026
	2017	—
	Thereafter	—
	Total	47,330
	Add: capital lease principal payments	1,438
	Total	48,768
	Less: current portion of long-term debt	(4,984		)
	Long-term debt, net of current portion	$	43,784

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Annual Lease Payments	'
	Future minimum annual lease payments under such leases are as follows (in thousands):
	Year Ending December 31,	Operating		Capital
	Remainder of 2013	$	1,014	$	132
	2014	3,431		527
	2015	2,768		466
	2016	1,369		423
	2017	216		82
	Thereafter	15		—
		$	8,813	1,630
	Less: amount representing interest			(192		)
	Present value of minimum lease payments			1,438
	Current portion of capital leases			(430		)
	Capital leases, less current portion			$	1,008

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Weighted Average Number of Common Shares Outstanding	'
	For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013				2012			2013			2012
	Numerator:
	Net loss	$	(14,510	)		$	(2,469	)	$	(21,820	)	$	(10,104	)
	Denominator:
	Weighted average common shares outstanding	97,318				90,216			96,940			89,812
	Weighted average unvested common shares subject to repurchase	(937		)		(713		)	(894		)	(590		)
	Weighted average common shares outstanding—basic	96,381				89,503			96,046			89,222
	Effect of dilutive securities:
	Options, warrants and restricted share awards	—				—			—			—
	Weighted average common shares outstanding—diluted	96,381				89,503			96,046			89,222
	Net loss per common share:
	Basic and diluted net loss per share	$	(0.15	)		$	(0.03	)	$	(0.23	)	$	(0.11	)
Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share	'
	he weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Options to purchase common stock	2,383			4,754			4,355		4,773
	Unvested restricted share awards	937			713			894		590
	Total	3,320			5,467			5,249		5,363

Segment_and_Geographical_Infor1

Segment and Geographical Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Revenues Attributed to Geographic Location of Customer	'
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	United States	$	33,696	$	30,980	$	99,249	$	96,430
	International	16,500		15,859		52,410		47,105
	Total consolidated revenues	$	50,196	$	46,839	$	151,659	$	143,535
Schedule of Long Lived Assets by Geographical Areas	'
	Total assets by region were as follows (in thousands):
		September 30,		December 31,
		2013		2012
	United States	$	195,708	$	213,912
	International	170,427		168,215
	Total consolidated assets	$	366,135	$	382,127

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
	Markets
Accounting Policies [Abstract]	'	'	'	'
Number of market for products	50	'	'	'
Cash and cash equivalents	$18,654,000	$22,241,000	$25,941,000	$20,666,000
Anticipated cash flow from operations and other working capital	$37,400,000	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Accounting Policies [Abstract]	'	'
Impairment of assets	$1.10	$1.10

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Details) (USD $)	1 Months Ended				0 Months Ended	9 Months Ended
	Apr. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Nov. 06, 2012	Nov. 06, 2012	Sep. 30, 2013
					Phygen, LLC [Member]	Phygen, LLC [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'
Number of unregistered shares issued to acquire business	'	'	'	'	4,069,087	'
Cash paid at closing of Purchase Agreement	'	'	'	'	$2,000,000	'
Unregistered shares of common stock placed in escrow account	'	'	'	'	1,170,960	'
Inventory step-up reversal period	'	'	'	'	'12 months	'
Cash paid to set-off for indemnification claims	4,000,000	'	'	'	'	'
Closing price of share	'	'	'	$1.69	'	'
Effective acquisition date	'	'	'	'	'	6-Nov-12
Net tangible assets assumed	'	'	'	'	1,100,000	1,086,000
Acquired intangible assets	'	'	'	'	8,900,000	'
Goodwill	'	181,390,000	180,838,000	'	8,500,000	8,514,000
Contingent consideration	'	'	'	'	$3,700,000	'

Acquisitions_Purchase_Price_Co

Acquisitions - Purchase Price Consideration Based on Common Stock and Cash Consideration (Details) (Phygen, LLC [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Phygen, LLC [Member]	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'
Fair value of Alphatec common stock issued upon closing	$8,856
Cash consideration paid and payable	5,900
Contingent consideration	3,724
Total purchase price	$18,480

Acquisitions_Allocation_of_Pur

Acquisitions - Allocation of Purchase Price and Estimated Useful Life of Assets Acquired (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Nov. 06, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified			Phygen, LLC [Member]	Phygen, LLC [Member]	Developed technology [Member]	Trademarks [Member]	Covenant not-to-compete [Member]	Customer-related intangibles [Member]	Distribution network [Member]
					Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]	Phygen, LLC [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Acquired intangibles, Useful lives (in years)	'	'	'	'	'3 years	'3 years	'3 years	'12 years	'12 years
Net tangible assets assumed, Estimated Fair Value	'	'	$1,086	$1,100	'	'	'	'	'
Acquired intangibles, Estimated Fair Value	'	'	'	8,900	176	59	389	5,843	2,413
Goodwill	181,390	180,838	8,514	8,500	'	'	'	'	'
Total purchase price allocation	'	'	$18,480	'	'	'	'	'	'

Select_Balance_Sheet_Details_A

Select Balance Sheet Details - Accounts Receivable, Net (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Receivables [Abstract]	'	'
Accounts receivable	$42,717	$42,086
Allowance for doubtful accounts	-979	-1,074
Accounts receivables, net	$41,738	$41,012

Select_Balance_Sheet_Details_I

Select Balance Sheet Details - Inventories, Net (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials, Gross	$5,291	$5,863
Work-in-process, Gross	519	1,350
Finished goods, Gross	61,439	59,864
Inventory, Gross, Total	67,249	67,077
Finished goods, Reserve for excess and obsolete	-24,110	-17,222
Inventories, net, Reserve for excess and obsolete	-24,110	-17,222
Raw materials, Net	5,291	5,863
Work-in-process, Net	519	1,350
Finished goods, Net	37,329	42,642
Inventories, Net	$43,139	$49,855

Select_Balance_Sheet_Details_P

Select Balance Sheet Details - Property and Equipment, Net (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$89,395	$82,719
Less accumulated depreciation and amortization	-59,880	-52,316
Property and Equipment, net	29,515	30,403
Surgical instruments [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'4 years	'
Property and Equipment, Gross	63,119	56,712
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'7 years	'
Property and Equipment, Gross	14,630	13,996
Computer equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'3 years	'
Property and Equipment, Gross	3,352	3,269
Office furniture and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'5 years	'
Property and Equipment, Gross	3,714	3,528
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Various Useful lives of property and equipments	'various	'
Property and Equipment, Gross	4,177	4,092
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'39 years	'
Property and Equipment, Gross	56	64
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	11	13
Construction in progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$336	$1,045

Select_Balance_Sheet_Details_A1

Select Balance Sheet Details - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Depreciation, Depletion and Amortization [Abstract]	'	'	'	'
Total depreciation expense	$3.70	$3.50	$10.90	$10.50
Total amortization expense	$3.70	$2.30	$9.10	$6.90

Select_Balance_Sheet_Details_I1

Select Balance Sheet Details - Intangible Assets, Net (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	$82,350	$81,088
Less accumulated amortization	-41,606	-34,232
Intangible assets, net	40,744	46,856
Developed product technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	23,475	23,253
Developed product technology [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'3 years	'
Developed product technology [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'8 years	'
Distribution rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'3 years	'
Intangible assets, Gross	2,480	4,281
Intellectual property [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'5 years	'
Intangible assets, Gross	1,004	1,004
License agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	17,186	17,423
License agreements [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'1 year	'
License agreements [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'7 years	'
Core technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Intangible assets, Gross	5,053	4,940
Trademarks and trade names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	3,868	3,796
Trademarks and trade names [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'3 years	'
Trademarks and trade names [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'9 years	'
Customer-related [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	21,923	19,221
Customer-related [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'12 years	'
Customer-related [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'15 years	'
Distribution network [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	4,027	3,906
Distribution network [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Distribution network [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'12 years	'
Physician education programs [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Intangible assets, Gross	3,109	3,039
Supply Agreement [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Intangible assets, Gross	$225	$225

Select_Balance_Sheet_Details_S

Select Balance Sheet Details - Schedule of Intangible assets, future amortization expense (Details) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
Remainder of 2013	$3,266
2014	6,121
2015	5,638
2016	5,320
2017	4,945
Thereafter	15,454
Total	$40,744

Select_Balance_Sheet_Details_S1

Select Balance Sheet Details - Schedule of Changes in Carrying Amount of Goodwill (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Goodwill [Roll Forward]	'
Balance at December 31, 2012	$180,838
Change in Phygen goodwill	-1,610
Effect of foreign exchange rate on goodwill	2,162
Balance at June 30, 2013	$181,390

License_and_Supply_Agreements_

License and Supply Agreements (Details) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Jan. 31, 2010	Sep. 30, 2013	Sep. 30, 2010	Sep. 30, 2013
					Distribution Agreement with Parcell Spine, LLC [Member]	Distribution Agreement with Parcell Spine, LLC [Member]	Distribution Agreement with Parcell Spine, LLC [Member]	Distribution Agreement with Parcell Spine, LLC [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'	'	'	'	'
Cash Payments	'	'	'	'	$500,000	'	$500,000	'
Milestone Payments	'	'	'	'	1,000,000	'	'	'
Issuance Of Common Stock	'	'	'	'	1,000,000	'	'	'
Addition To Intangible Assets	'	'	'	'	'	'	1,500,000	'
Number Of Shares Of Common Stock For Issuance	'	'	'	'	'	'	476,190	'
Amortization of acquired intangible assets	741,000	491,000	2,255,000	1,574,000	'	900,000	'	900,000
Provision for excess and obsolete inventory	'	'	$10,842,000	$3,980,000	'	$2,600,000	'	$2,600,000

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)

1 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

Feb. 28, 2013

Sep. 30, 2013

Sep. 30, 2012

Jun. 07, 2012

Sep. 30, 2013

Aug. 30, 2013

Sep. 30, 2013

Jul. 30, 2013

Sep. 30, 2013

Aug. 30, 2013

Aug. 30, 2013

Aug. 30, 2013

Sep. 30, 2013

Aug. 30, 2013

Silicon Valley Bank [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan Drawn On Closing [Member]

Term Loan. Delayed Draw [Member]

Credit Facility [Member]

Credit Facility [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

$50,000,000

'

$73,000,000

'

$50,000,000

'

$33,000,000

$28,000,000

$5,000,000

'

$40,000,000

Repayments of Lines of Credit

'

130,017,000

65,225,000

'

'

28,000,000

'

'

'

'

'

'

'

'

Interest rate description

'

'

'

'

'

'

'

'

'( "LIBOR") plus 8.0%

'

'

'

'LIBOR plus 6.0%

'

Debt, spread on variable rate

'

'

'

'

'

'

'

'

8.00%

'

'

'

6.00%

'

Floor on interest rate

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

Interest rate of revolving line of credit

'

'

'

'

'

'

'

'

9.50%

'

'

'

6.20%

'

Term loan payments

'

'

'

'

8,100,000

'

300,000

'

'

'

'

'

'

'

Credit Facility used to pay off its existing term loan

'

34,300,000

'

'

'

'

'

'

'

'

'

'

'

'

Existing line of credit

'

'

'

'

17,600,000

'

'

'

'

'

'

'

'

'

Borrowing capacity

'

'

'

40,000,000

'

'

'

'

'

'

'

'

'

'

Early termination and other fees

'

2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance and debt discount costs

'

600,000

'

'

'

'

400,000

'

'

'

'

'

'

'

Loss on extinguishment of debt costs

'

'

2,900,000

'

'

'

'

'

'

'

'

'

'

'

Up-front commitment fee

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs

'

200,000

'

'

'

400,000

'

'

'

'

'

'

'

'

Additional interest rate to be charged in the event of default

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

Amendment fee

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Principal_Payments_on_Deb

Debt - Principal Payments on Debt (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'	'
Remainder of 2013	$1,340	'
2014	3,964	'
2015	3,000	'
2016	39,026	'
2017	0	'
Thereafter	0	'
Total long term debt	47,330	'
Add: capital lease principal payments	1,438	'
Total	48,768	'
Less: current portion of long-term debt	-4,984	-1,700
Long-term debt, net of current portion	$43,784	$39,967

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

In Millions, unless otherwise specified

31-May-08

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2004

Jul. 31, 2005

Sep. 30, 2013

31-May-08

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Scient'x [Member]

Surgiview [Member]

Eurosurgical [Member]

HealthpointCapital [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Scient'x [Member]

HealthpointCapital [Member]

Scient'x [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Capital leases expire date

'

'

'

30-Jun-17

'

'

'

'

'

'

'

'

Lease interest rate

'

'

'

'

'

'

'

'

'

6.60%

'

9.60%

Rent expense

'

$0.90

$0.90

$2.90

$2.80

'

'

'

'

'

'

'

Judgment assessed by court

'

'

'

30

'

'

'

9

'

'

'

'

Business acquisition, percentage of interest acquired

'

'

'

'

'

33.10%

73.00%

'

'

'

'

'

Loss Contingency, Damages Sought, Value

$39

'

'

'

'

'

'

'

$39

$55

$55

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Annual Lease Payments (Details) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Leases [Abstract]	'
Operating leases Remainder of 2013	$1,014
Operating leases 2014	3,431
Operating leases 2015	2,768
Operating leases 2016	1,369
Operating leases 2017	216
Operating leases Thereafter	15
Operating leases, Future Minimum Payments Due, Total	8,813
Capital leases Remainder of 2013	132
Capital leases 2014	527
Capital leases 2015	466
Capital leases 2016	423
Capital leases 2017	82
Capital leases Thereafter	0
Total Capital leases	1,630
Less: amount representing interest	-192
Present value of minimum lease payments	1,438
Current portion of capital leases	-430
Capital leases, less current portion	$1,008

Net_Loss_Per_Share_Weighted_Av

Net Loss Per Share - Weighted Average Number of Common Shares Outstanding (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net loss	($14,510)	($2,469)	($21,820)	($10,104)
Denominator:	'	'	'	'
Weighted average common shares outstanding	97,318,000	90,216,000	96,940,000	89,812,000
Weighted average unvested common shares subject to repurchase	-937,000	-713,000	-894,000	-590,000
Weighted average common shares outstanding-basic	96,381,000	89,503,000	96,046,000	89,222,000
Effect of dilutive securities:	'	'	'	'
Options, warrants and restricted share awards	0	0	0	0
Weighted average common shares outstanding-diluted	96,381,000	89,503,000	96,046,000	89,222,000
Net loss per common share:	'	'	'	'
Basic and diluted net loss per share	($0.15)	($0.03)	($0.23)	($0.11)

Net_Loss_Per_Share_WeightedAve

Net Loss Per Share - Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	3,320	5,467	5,249	5,363
Options to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	2,383	4,754	4,355	4,773
Unvested restricted share awards [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities not included in diluted net loss per share	937	713	894	590

Equity_Transactions_Additional

Equity Transactions - Additional Information (Details) (Media Advertising Agreement [Member], USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	31-May-13
Media Advertising Agreement [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Consulting fees paid	$0.20
Restricted stock issued	225,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits increase	$0.70
Unrecognized tax benefits	$6.60
Income tax examination, year under examination	'2011

Segment_and_Geographical_Infor2

Segment and Geographical Information - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
	Location	Location	Segment	Location
			Location
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of operating segments	'	'	1	'
Number of reportable business segment	'	'	1	'
Number of geographic regions	2	2	2	2
Revenue	$50,196	$46,839	$151,659	$143,535
Japan [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Minimum percentage of revenues	'	10.00%	'	10.00%
Revenue	$7,300	$7,500	$20,800	$21,000

Segment_and_Geographical_Infor3

Segment and Geographical Information - Schedule of Revenues Attributed to Geographic Location of Customer (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	$50,196	$46,839	$151,659	$143,535
Reportable Geographical Components [Member] | United States [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	33,696	30,980	99,249	96,430
Reportable Geographical Components [Member] | International [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Total consolidated revenues	$16,500	$15,859	$52,410	$47,105

Segment_and_Geographical_Infor4

Segment and Geographical Information - Schedule of Long Lived Assets by Geographical Areas (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$366,135	$382,127
Reportable Geographical Components [Member] | United States [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	195,708	213,912
Reportable Geographical Components [Member] | International [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$170,427	$168,215

Restructuring_Details

Restructuring (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'
Additional inventory reserve	$4.50	$5
Facility Closing [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
One-time facility closing and contract termination costs	11	'
Accrued Expenses [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Employee severance and benefits accruals	4	4
Restructuring Charges [Member] | Employee Severance [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Severance Costs	$4	$4

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
HealthpointCapital [Member]	'	'
Related Party Transaction [Line Items]	'	'
Incurred expenses	$0.10	'
Payable liability	0.1	'
New York Orthotec matter [Member]	'	'
Related Party Transaction [Line Items]	'	'
Legal expenses	$1.30	$1.90

Subsequent_Event_Details

Subsequent Event (Details) (USD $)	Nov. 06, 2012	Oct. 22, 2013
In Millions, except Per Share data, unless otherwise specified		Collaborative Arrangement [Member]
		Subsequent Event [Member]
		payment
Subsequent Event [Line Items]	'	'
Term of Agreement	'	'3 years
Periodic Payments For Services Provided, Number	'	3
Periodic Payments for Services Provided, Amount	'	$8
Closing price of share	$1.69	$1.95